Drug Profile

ATP R13

Alternative Names: ATP-R-13

Latest Information Update: 24 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Zurich
Developer Atopia Therapeutics
Class Anti-inflammatories; Antiasthmatics; Recombinant proteins
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Allergic asthma

Most Recent Events

24 Feb 2026 Preclinical trials in Allergic asthma in Switzerland (PO) before February 2026 (Atopia Therapeutics pipeline, February 2026)
24 Feb 2026 Adverse events data from preclinical studies in allergic asthma released by Atopia Therapeutics (Atopia Therapeutics pipeline, February 2026)
24 Feb 2026 Atopia Therapeutics plans a phase I trial for Allergic asthma in 2028

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com